FDA Issues Voluntary Recall of Duloxetine Due to Carcinogenic Impurities
The FDA has issued a voluntary recall of the antidepressant duloxetine due to carcinogenic impurities, specifically N-nitroso-duloxetine. Rising Pharmaceuticals initiated the recall affecting over 233,000 bottles, highlighting ongoing concerns about nitrosamine contamination in medications. Patients are advised to consult healthcare providers for guidance and alternative treatment options. Stay informed about medication safety and recalls to protect your health.
Tragic Death of 18-Year-Old Sparks Urgent Call for Improved Mental Health Care
The tragic death of 18-year-old Emily Burns in Waltham Forest has ignited urgent discussions on mental health care for adolescents. An inquest revealed significant gaps in her treatment, highlighting the need for improved support systems for young individuals transitioning from adolescent to adult mental health services. Emily’s story underscores the critical importance of comprehensive care and family involvement in mental health treatment.
FDA Issues Class II Recall for Duloxetine Capsules Over Health Concerns
The FDA has issued a Class II recall for over 7,100 bottles of Duloxetine Delayed-Release Capsules due to elevated levels of a harmful chemical, N-nitroso-duloxetine. Patients are urged to consult healthcare professionals before making any changes to their medication. This recall highlights the FDA’s commitment to drug safety and public health.
Antidepressants and Heat: Understanding the Risks
Learn about the potential impact of SSRIs and other psychiatric medications on heat tolerance. Dr. Judith Joseph explains how these medications can disrupt the body’s ability to regulate temperature, sweat production, and heat perception. Find out what precautions individuals can take during the summer season to reduce the risks associated with medication-induced heat sensitivity.